-
-
Overview
-
Please contact us at for specific academic pricing.
Background
Dihydroergotamine mesylate is a partial agonist for both dopaminergic and α-adrenergic receptors. Dihydroergotamine mesylate also acts as a full agonist for the 5-HT receptor, with IC50 values being 2 nM and 2.2 nM for human 5-HT1B and 5-HT1D receptors stably expressed in HEK 293 cells and C6 glioma cells, respectively. Like other potent 5-HT receptor agonists such as sumatriptan, dihydroergotamine mesylate has been approved for acute migraine therapy.
1. Lesage AS, Wouters R, Van Gompel P, et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. British Journal of Pharmacology, 1998, 123(8): 1655-1665.
2. Schaerlinger B, Hickel P, Etienne N, et al. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. British Journal of Pharmacology, 2003, 140(2): 277-284.
3. Villalón CM, Bom AH, Den Boer MO, et al. Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. Pharmacological Research, 1992, 25(2): 125-137.
-
- Properties
-
Overview